🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excellent discussion. Audience questions mostly future of #CART, where will it be used in next decade and scope with non cancer diseases KU Cancer Center #HemOncReview Prakash Neupane Al-Ola A Abdallah MD (USMIRC) Anusha MD Abdulraheem Yacoub

Al-Ola A Abdallah MD (USMIRC) KU Cancer Center OncoAlert USMIRC News Dr. Abdallah on podium. Myeloma update.

Global access to novel MM therapies remains challenging, barriers and suggested strategies to bridge the gap. Global Access to Multiple Myeloma Therapies | JCO Global Oncology ascopubs.org/doi/full/10.12…

📢 Excited to share our multicenter study just published in Clinical Lymphoma, Myeloma & Leukemia: “Real-world outcomes of sequential BCMA therapies in RRMM after belantamab” 🔗 clinical-lymphoma-myeloma-leukemia.com/article/S2152-… Shout-out to Hamza Hashmi Racheldileo With: Yue Yin Christopher Strouse

Congrats Prerna Mewawalla and all group on current publication “Real-world outcomes of sequential BCMA therapies in RRMM after belantamab” 🎊🎉👍🏻 OncoAlert USMIRC News #USMIRC #MedEd #MedTwitter #mmsm #myeloma #سرطان_الدم #المايلوما

This is a major win for patients . we have been advocating this with our publications on access ! Finally - REMS is revised and product labeling revision to include 2 weeks monitoring and driving restriction and not 4 weeks. 👍🏼 -monitor patients for at least 2 wk, with daily

ICE-T: Where immune cell therapy meets bold ideas, real talk, and the people actually doing the work. Don’t just hear about it—be there. Whether you're in the clinic or the classroom, ICE-T delivers practical updates for nurses, APPs, and physicians in both community and academic

CD19 CAR T-cell–derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy Blood Advances ashpublications.org/bloodadvances/…

FDA approved third BCMA targeting T Cell engager Antibody for 4 prior lines of therapy Myeloma patients fda.gov/drugs/resource…

In-vivo CAR Ts for myeloma are going to come fast and furious. These products are engineering marvels. ESO-T01 (EsoBiotec) is an anti-BCMA in-vivo CAR T that: 1) Delivers the CAR transgene to endogenous T-cells, reprogramming them to CAR T cells in situ 2) Overexpress CD47 to

Primary impact of clonal hematopoiesis on the outcomes of BCMA CAR-T in MM: prolonged transfusion-dependent cytopenias #mmsm #bmtsm Noopur Raje Blood Journals Portfolio ashpublications.org/bloodadvances/…

Even small amounts of alcohol can increase your risk of cancer - but most people don’t know it. Learn how alcohol affects your body and what you can do to reduce your risk ➜ bit.ly/4nDPspc #CancerPrevention #CancerRisk #AlcoholAndCancer

The FDA recently updated its guidelines for CAR T-cell therapy, cutting the monitoring time from 4 weeks to 2. Researchers at KU Cancer Center helped shape this change through early work that challenged how care is delivered. Learn more from Nausheen Ahmed MD ➜

Expanding Access to CAR T-Cell Therapy How KU Cancer Center researchers helped make CAR T-cell therapy more accessible by Nausheen Ahmed MD 🧵1/ Big win for cancer patients! 🧬🚗 In 2025, the FDA made a game-changing decision to ease restrictions around CAR T-cell therapy. And

Just out: key safety reporting patterns for TCEs in multiple myeloma Faiza Humayun Khan Nausheen Ahmed MD Al-Ola A Abdallah MD (USMIRC) KU Cancer Center Zahra M, PharmD, MBA, BCOP, FHOPA Cortex Innovation #hemeonc cureus.com/articles/38058…

ASCT could still be considered in patients with primary refractory or early relapse in centers with limited access to CAR-T therapy. ow.ly/Qqqx50Wnby5 #lymphoidneoplasia #transplantation